Resveratrol protects cardiomyocytes from doxorubicin-induced apoptosis through the AMPK/P53 pathway

Molecular Medicine Reports

Volumn 13, Issue 2, 2016, Pages 1281-1286

  Liu, Mi Hua ^a   Lin, Xiao Long ^b   Guo, Dong Ming ^a   Zhang, Yuan ^c   Yuan, Cong ^d   Tan, Tian Ping ^a   Chen, Yu Dan ^a   Wu, Shao Jian ^a   Ye, Zu Feng ^a   He, Jun ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c Hunan Provincial Mawangdui Hospital   (China)

^d Department of Neurosurgery The First Hospital of Changsha   (China)

Author keywords

Adenosine monophosphate activated protein kinase; Apoptosis; Doxorubicin; P53; Resveratrol

Indexed keywords

DOXORUBICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RESVERATROL; STILBENE DERIVATIVE;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CARDIOTOXICITY; CELL CULTURE; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME PHOSPHORYLATION; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; HUMAN CELL; MTT ASSAY; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CARDIAC MUSCLE CELL; CELL LINE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; RAT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE; DOXORUBICIN; GENE EXPRESSION REGULATION; HUMANS; MYOCYTES, CARDIAC; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; SIGNAL TRANSDUCTION; STILBENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84956872444     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4665     Document Type: Article

References (25)

1. Menna P, Recalcati S, Cairo G and Minotti G: An introduction to the metabolic determinants of anthracycline cardiotoxicity. Cardiovasc Toxicol 7: 80-85, 2007.
2. Lipshultz SE, Karnik R, Sambatakos P, Franco VI, Ross SW and Miller TL: Anthracycline-related cardiotoxicity in childhood cancer survivors. Curr Opin Cardiol 29: 103-112, 2014.
3. Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, Rossettin P, Ghigliotti G, Ballestrero A, Patrone F, et al: Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37: 837-846, 2004.
4. Renaud J, Bournival J, Zottig X and Martinoli MG: Resveratrol protects DAergic PC12 cells from high glucose-induced oxidative stress and apoptosis: Effect on p53 and GRP75 localization. Neurotox Res 25: 110-123, 2014.
5. Liu MH, Yuan C, He J, Tan TP, Wu SJ, Fu HY, Liu J, Yu S, Chen YD, Le QF, et al: Resveratrol protects PC12 cells from high glucose-induced neurotoxicity Via PI3K/Akt/FoxO3a pathway. Cell Mol Neurobiol 35: 513-522, 2015.
6. Das S, Falchi M, Bertelli A, Maulik N and Das DK: Attenuation of ischemia/reperfusion injury in rats by the anti-infl ammatory action of resveratrol. Arzneimittelforschung 56: 700-706, 2006.
7. Tatlidede E, Sehirli O, Velioʇlu-Oʇünc A, Cetinel S, Yeʇen BC, Yarat A, Süleymanoʇlu S and Sener G: Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic Res 43: 195-205, 2009.
8. Shankar S, Singh G and Srivastava RK: Chemoprevention by resveratrol: Molecular mechanisms and therapeutic potential. Front Biosci 12: 4839-4854, 2007.
9. Rezk YA, Balulad SS, Keller RS and Bennett JA: Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: Study in human gynecologic cancer cell lines and in rodent heart. Am J Obstet Gynecol 194: e23-e26, 2006.
10. Park DG: Antichemosensitizing effect of resveratrol in cotreatment with oxaliplatin in HCT116 colon cancer cell. Ann Surg Treat Res 86: 68-75, 2014.
11. Chen L, Xu B, Liu L, Luo Y, Yin J, Zhou H, Chen W, Shen T, Han X and Huang S: Hydrogen peroxide inhibits mTOR signaling by activation of AMPKalpha leading to apoptosis of neuronal cells. Lab Invest 90: 762-773, 2010.
12. Towler MC and Hardie DG: AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100: 328-341, 2007.
13. Chen MB, Wu XY, Gu JH, Guo QT, Shen WX and Lu PH: Activation of AMP-activated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells. Cell Biochem Biophys 60: 311-322, 2011.
14. Okoshi R, Ozaki T, Yamamoto H, Ando K, Koida N, Ono S, Koda T, Kamijo T, Nakagawara A and Kizaki H: Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem 283: 3979-3987, 2008.
15. Liu J, Mao W, Ding B and Liang CS: ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am J Physiol Heart Circ Physiol 295: H1956-H1965, 2008.
16. Guo R, Lin J, Xu W, Shen N, Mo L, Zhang C and Feng J: Hydrogen sulfide attenuates doxorubicin-induced cardiotoxicity by inhibition of the p38 MAPK pathway in H9c2 cells. Int J Mol Med 31: 644-650, 2013.
17. Gu J, Hu W and Zhang DD. Resveratrol, a polyphenol phytoalexin, protects against doxorubicin-induced cardiotoxicity. J Cell Mol Med 19: 2324-2328.
18. Wang X, Wang XL, Chen HL, Wu D, Chen JX, Wang XX, Li RL, He JH, Mo L, Cen X, et al: Ghrelin inhibits doxorubicin cardiotoxicity by inhibiting excessive autophagy through AMPK and p38-MAPK. Biochem Pharmacol 88: 334-350, 2014.
19. Guo R, Wu K, Chen J, Mo L, Hua X, Zheng D, Chen P, Chen G, Xu W and Feng J: Exogenous hydrogen sulfide protects against doxorubicin-induced inflammation and cytotoxicity by inhibiting p38MAPK/NFkB pathway in H9c2 cardiac cells. Cell Physiol Biochem 32: 1668-1680, 2013.
20. Das DK, Mukherjee S and Ray D: Erratum to: Resveratrol and red wine, healthy heart and longevity. Heart Fail Rev 16: 425-435, 2011.
21. Oktem G, Uysal A, Oral O, Sezer ED, Olukman M, Erol A, Akgur SA and Bilir A: Resveratrol attenuates doxorubicin-induced cellular damage by modulating nitric oxide and apoptosis. Exp Toxicol Pathol 64: 471-479, 2012.
22. Shirwany NA and Zou MH: AMPK: A cellular metabolic and redox sensor. A minireview. Front Biosci (Landmark Ed) 19: 447-474, 2014.
23. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
24. Wang S, Song P and Zou MH: Inhibition of AMP-activated protein kinase alpha (AMPKα) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: Role of p53 and SIRT1. J Biol Chem 287: 8001-8012, 2012.
25. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ and Thompson CB: AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18: 283-293, 2005.